Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
== Research, teaching and training == As of 2025, the Department of Biochemistry, Cell and Systems Biology is composed of 46 tenured and tenure-track research-focused teaching academics, studying the Departmental research themes of cell biology, systems and computational biology, cell signaling, multiomics, photosynthesis and plants and mechanistic structural biology. The department is home to a broad selection of Early Career Researchers and senior Professorial staff including Sonia Rocha, a specialist in Hypoxia-inducible factor, Dan Rigden, noted for his work with CASP Douglas Kell, a leader in systems and synthetic biology, Claire Eyers, a proteomics and biological mass spectrometry expert, Luning Liu, Ben Goult, J Bernadette Moore, Richard Scheltema, Sylvie Urbe and Roy Goodacre, editor of the peer-reviewed journal Metabolomics (journal). The department possesses dedicated research, mentoring and technical professional support staff, all of whom were recognised through the award of a Gold Athena Swan Award in 2025, one of only a handful of Institutes in the UK to achieve this distinction,. Grant-funded research from across the UKRI, Wellcome, industrial and charity portfolios is performed in state-of-the-art facilities where biochemical approaches sit alongside cutting-edge multiomics technology to study the chemistry of life.
In 2018, the Chinese state-owned Harbin Pharmaceutical Group agreed to acquire an approximately 40% stake in GNC. In September 2020, Senator Marco Rubio asked the Committee on Foreign Investment in the United States to examine the proposed acquisition on data protection and national security grounds. In November 2018, the company announced they would be closing up to 900 stores over 3 years. In July 2019, it was announced that they planned to close up to 1,400 company owned retail locations, primarily those located within shopping malls. In June 2020, GNC filed for Chapter 11 bankruptcy protection due to the negative impact of the COVID-19 Lockdowns and Stay-at-home orders that severely impacted store traffic; resulting in the closure of at least 800 stores. Effective on June 30, 2020, the stock was delisted from the New York Stock Exchange and shifted to the OTC Markets Group. In September 2020, the bankruptcy court in Delaware approved the private sale of GNC for $770 million to Harbin Pharmaceutical Group and CITIC Capital. In October 2020, Harbin Pharmaceutical Group, a Chinese state-owned pharmaceutical manufacturer, acquired the remainder of the company. The company was sold under a private 363 sale thus cancelling the Chapter 11 process under the new ownership of Harbin Pharmaceutical Group in October 2020. In 2021, GNC revealed that Josh Burris will take over as CEO, Nate Frazier as COO and Cam Lawrence as CFO. In 2021, GNC announced a partnership with Walmart for a selection of GNC specific products.
=== Waxing and oiling === Historically, light waxing and oiling were the first treatments used in ancient times, providing a wetting effect, thereby enhancing the colour and lustre. This treatment is more or less acceptable by tradition, especially because treated turquoise is usually of a higher grade to begin with. Oiled and waxed stones are prone to "sweating" under even gentle heat or if exposed to too much sun, and they may develop a white surface film or bloom over time. (With some skill, oil and wax treatments can be restored.)
Sources: en.wikipedia.org
=== Cancer === In cancer, tumours take over the body's vascularisation processes to supply themselves with blood, helping them grow and spread. Anti-angiogenic therapies are currently used in combination with other therapies for cancer management. Bevacizumab, a monoclonal antibody & VEGF inhibitor is approved for use in cancer treatment.
In cpDNA, there are several A → G deamination gradients. DNA becomes susceptible to deamination events when it is single stranded. When replication forks form, the strand not being copied is single stranded, and thus at risk for A → G deamination. Therefore, gradients in deamination indicate that replication forks were most likely present and the direction that they initially opened (the highest gradient is most likely nearest the start site because it was single stranded for the longest amount of time). This mechanism is still the leading theory today; however, a second theory suggests that most cpDNA is actually linear and replicates through homologous recombination. It further contends that only a minority of the genetic material is kept in circular chromosomes while the rest is in branched, linear, or other complex structures. One of competing model for cpDNA replication asserts that most cpDNA is linear and participates in homologous recombination and replication structures similar to the linear and circular DNA structures of bacteriophage T4. It has been established that some plants have linear cpDNA, such as maize, and that more species still contain complex structures that scientists do not yet understand. When the original experiments on cpDNA were performed, scientists did notice linear structures; however, they attributed these linear forms to broken circles.
=== Valorization and circular economy === Recent trends in the dairy industry focus on a circular economy approach, transforming whey treatment plants into biorefineries. Instead of producing only biogas, processes can be tuned for acidogenic fermentation to produce volatile fatty acids (VFAs) via the carboxylate platform. Recent findings suggest that applying thermal and alkaline pre-treatments to the inoculum can effectively halt methanogenesis, thereby favoring the accumulation of VFAs, which serve as valuable precursors for bioplastics and other chemicals. Integrated systems coupling anaerobic digestion with microalgae cultivation have also been proposed. In these "closed-loop" scenarios, the nutrient-rich digestate serves as a substrate for microalgal biomass production, which can be harvested for biofuels or high-value pigments, while simultaneously recovering nitrogen and phosphorus (e.g., as struvite).
As of 2019, Illinois had $8.5 billion of unpaid bills and $134 billion of pension liabilities. The gas tax that funds the 2019 infrastructure plan, 38 cents per gallon and indexed to inflation, took effect on July 1, 2019. As of 2019, Illinois had one of the highest fuel taxes in the U.S. In 2024, Pritzker signed legislation eliminating the state's 1% tax on groceries, beginning January 1, 2026. In 2024, Pritzker signed a budget into law that included the creation of the state's first child tax credit, which provided up to $300 to households with children under 12 years old that made less than $60,000 annually. In 2025, the tax credit doubled to up to $600 per child.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.